{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:01:23Z","timestamp":1775318483742,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmogo.2025.100295","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:50:18Z","timestamp":1768805418000},"page":"100295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Ciardiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.P.","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3435","authenticated-orcid":false,"given":"E.","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-6723","authenticated-orcid":false,"given":"P.","family":"Parente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vallarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Viola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7004-6862","authenticated-orcid":false,"given":"G.","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Febbraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0704","authenticated-orcid":false,"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmogo.2025.100295_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","article-title":"Targeting the EGFR signalling pathway in metastatic colorectal cancer","volume":"9","author":"Napolitano","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100295_bib2","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100295_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100295_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.annonc.2024.08.2334","article-title":"Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS\/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial","volume":"35","author":"Ciardiello","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2025.100295_bib5","article-title":"Negative ultraselection of patients with RAS\/BRAF wild-type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-based therapy","volume":"6","author":"Randon","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100295_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100295_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104511","article-title":"Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial","volume":"10","author":"Ciardiello","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmogo.2025.100295_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115642","article-title":"Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: findings from the CAPRI-2 GOIM study","volume":"226","author":"Ciardiello","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2025.100295_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115399","article-title":"Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: an exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer","volume":"221","author":"Weiss","year":"2025","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmogo.2025.100295_bib10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-23-3023","article-title":"Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212)","volume":"30","author":"Stahler","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmogo.2025.100295_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113396","article-title":"Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU\/LV","volume":"195","author":"Pietrantonio","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2025.100295_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115471","article-title":"Advances and challenges in targeted therapies for HER2-amplified colorectal cancer","volume":"222","author":"Pizzamiglio","year":"2025","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmogo.2025.100295_bib13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100295_bib14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100295_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmogo.2025.100295_bib16","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100295_bib17","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100295_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100295_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jamaoncol.2018.7229","article-title":"HER2 amplification and anti-EGFR sensitivity in advanced colorectal cancer","volume":"5","author":"Bregni","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmogo.2025.100295_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102488","article-title":"The predictive role of ERBB2 point mutations in metastatic colorectal cancer: a systematic review","volume":"112","author":"Vaghi","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"29","key":"10.1016\/j.esmogo.2025.100295_bib21","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1200\/JCO-25-01003","article-title":"Impact of human epidermal growth factor receptor 2 in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab or anti-EGFRs: exploratory analysis of eight randomized trials","volume":"43","author":"Germani","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2025.100295_bib22","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1002\/jcp.27984","article-title":"HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy","volume":"234","author":"Gharib","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.esmogo.2025.100295_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1069370","article-title":"Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS\/BRAF wild type tumors at start of first line: the CAPRI 2 GOIM trial","volume":"13","author":"Martini","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmogo.2025.100295_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00226","article-title":"Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"3","author":"Raghav","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.esmogo.2025.100295_bib25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","article-title":"HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer","volume":"24","author":"Sartore-Bianchi","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100295_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/14796694.2024.2441101","article-title":"MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer","volume":"21","author":"Strickler","year":"2025","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2025.100295_bib27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:05:30Z","timestamp":1775315130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S2949819825001645"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100295","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100295"}}